Exact Mass: 508.0091

Exact Mass Matches: 508.0091

Found 24 metabolites which its exact mass value is equals to given mass value 508.0091, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Inosine triphosphate

({[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-hydroxy-9H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid

C10H15N4O14P3 (507.9798)


Inosine triphosphate (ITP) is an intermediate in the purine metabolism pathway. Relatively high levels of ITP in red cells are found in individuals as result of deficiency of inosine triphosphatase (EC 3.1.3.56, ITPase) ITPase is a cytosolic nucleoside triphosphate pyrophosphohydrolase specific for ITP catalysis to inosine monophosphate (IMP) and deoxy-inosine triphosphate (dITP) to deoxy-inosine monophosphate. ITPase deficiency is not associated with any defined pathology other than the characteristic and abnormal accumulation of ITP in red blood cells. Nevertheless, ITPase deficiency may have pharmacogenomic implications, and the abnormal metabolism of 6-mercaptopurine in ITPase-deficient patients may lead to thiopurine drug toxicity. ITPases function is not clearly understood but possible roles for ITPase could be to prevent the accumulation of rogue nucleotides which would be otherwise incorporated into DNA and RNA, or compete with nucleotides such as GTP in signalling processes. (PMID : 170291, 1204209, 17113761, 17924837) [HMDB] Inosine triphosphate (ITP) is an intermediate in the purine metabolism pathway. Relatively high levels of ITP in red cells are found in individuals as result of deficiency of inosine triphosphatase (EC 3.1.3.56, ITPase) ITPase is a cytosolic nucleoside triphosphate pyrophosphohydrolase specific for ITP catalysis to inosine monophosphate (IMP) and deoxy-inosine triphosphate (dITP) to deoxy-inosine monophosphate. ITPase deficiency is not associated with any defined pathology other than the characteristic and abnormal accumulation of ITP in red blood cells. Nevertheless, ITPase deficiency may have pharmacogenomic implications, and the abnormal metabolism of 6-mercaptopurine in ITPase-deficient patients may lead to thiopurine drug toxicity. ITPases function is not clearly understood but possible roles for ITPase could be to prevent the accumulation of rogue nucleotides which would be otherwise incorporated into DNA and RNA, or compete with nucleotides such as GTP in signalling processes. (PMID: 170291, 1204209, 17113761, 17924837).

   

dXTP

[[(2R,3S,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

C10H15N4O14P3 (507.9798)


   

[[(2R,5R)-3,4-Dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

({[({[3,4-dihydroxy-5-(6-oxo-6,9-dihydro-1H-purin-9-yl)oxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid

C10H15N4O14P3 (507.9798)


   
   
   

Inosine triphosphate

Inosine triphosphate

C10H15N4O14P3 (507.9798)


The inosine phosphate that has a triphosphate group at the 5-position. It is an intermediate in the metabolism of purine.

   

Inosine 5-triphosphate

Inosine 5-triphosphate

C10H15N4O14P3 (507.9798)


   

4-METHYL-2-(2-(6-CHLORO-3-METHYL-2(3H)-BENZOXAZOLINYLIDENE)-1-PROPENYL)-3-PHENYL THIAZOLINIUM IODIDE

4-METHYL-2-(2-(6-CHLORO-3-METHYL-2(3H)-BENZOXAZOLINYLIDENE)-1-PROPENYL)-3-PHENYL THIAZOLINIUM IODIDE

C21H18ClIN2OS (507.9873)


   

sodium 6-[(4-amino-3-bromo-9,10-dihydro-9,10-dioxo-1-anthryl)amino]toluene-3-sulphonate

sodium 6-[(4-amino-3-bromo-9,10-dihydro-9,10-dioxo-1-anthryl)amino]toluene-3-sulphonate

C21H14BrN2NaO5S (507.9704)


   

Diphenyl(o-tolyl)phosphine gold(I) chloride

Diphenyl(o-tolyl)phosphine gold(I) chloride

C19H17AuClP (508.0422)


   

1,5-Cyclooctadiene(hexafluoroacetylacetonato)iridium(I)

1,5-Cyclooctadiene(hexafluoroacetylacetonato)iridium(I)

C13H13F6IrO2 (508.0449)


   

4,6-Dibromothieno[3,4-b]thiophene-2-carboxylic acid dodecyl ester

4,6-Dibromothieno[3,4-b]thiophene-2-carboxylic acid dodecyl ester

C19H26Br2O2S2 (507.9741)


   

Bromo(tetraphenyl)stiborane

Bromo(tetraphenyl)stiborane

C24H20BrSb (507.9787)


   

trichloropyranthrene-8,16-dione

trichloropyranthrene-8,16-dione

C30H11Cl3O2 (507.9825)


   

disodium 3-[[2-(acetylamino)-4-aminophenyl]azo]naphthalene-1,5-disulphonate

disodium 3-[[2-(acetylamino)-4-aminophenyl]azo]naphthalene-1,5-disulphonate

C18H14N4Na2O7S2 (508.0099)


   

1,1,2,2-tetrafluoroethene,2,2,3,3-tetrafluoro-3-[1,1,1,2,3,3-hexafluoro-3-(1,2,2-trifluoroethenoxy)propan-2-yl]oxypropanoic acid

1,1,2,2-tetrafluoroethene,2,2,3,3-tetrafluoro-3-[1,1,1,2,3,3-hexafluoro-3-(1,2,2-trifluoroethenoxy)propan-2-yl]oxypropanoic acid

C10HF17O4 (507.9603)


   

Linzagolix

Linzagolix

C22H15F3N2O7S (508.0552)


H - Systemic hormonal preparations, excl. sex hormones and insulins > H01 - Pituitary and hypothalamic hormones and analogues > H01C - Hypothalamic hormones > H01CC - Anti-gonadotropin-releasing hormones C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist > C2092 - Gonadotropin Releasing Hormone Antagonist

   

2-Deoxy-2-azidocytidine triphosphate

2-Deoxy-2-azidocytidine triphosphate

C9H15N6O13P3 (507.991)


   

Ethyl 2-[4-[(2,4-dichlorobenzoyl)carbamothioylamino]-3-methylphenyl]-3,3,3-trifluoro-2-hydroxypropanoate

Ethyl 2-[4-[(2,4-dichlorobenzoyl)carbamothioylamino]-3-methylphenyl]-3,3,3-trifluoro-2-hydroxypropanoate

C20H17Cl2F3N2O4S (508.0238)


   

N-(4-hydroxy-3-iodo-5-nitrophenylacetyl)-beta-alanylglycylglycine

N-(4-hydroxy-3-iodo-5-nitrophenylacetyl)-beta-alanylglycylglycine

C15H17IN4O8 (508.0091)


   

[[(2R,3S,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

[[(2R,3S,5R)-5-(2,6-dioxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

C10H15N4O14P3 (507.9798)


   

PD0325901-O-C2-dioxolane

PD0325901-O-C2-dioxolane

C18H16F3IN2O4 (508.0107)


PD0325901-O-C2-dioxolane has main portion of MEK inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader[1].

   

1-[3-(acetyloxy)-5-[(3-bromopropa-1,2-dien-1-yl)oxy]oxolan-2-yl]-3-bromooct-5-en-2-yl acetate

1-[3-(acetyloxy)-5-[(3-bromopropa-1,2-dien-1-yl)oxy]oxolan-2-yl]-3-bromooct-5-en-2-yl acetate

C19H26Br2O6 (508.0096)


   

(2s,3s,5e)-1-[(2r,3r,5r)-3-(acetyloxy)-5-[(3-bromopropa-1,2-dien-1-yl)oxy]oxolan-2-yl]-3-bromooct-5-en-2-yl acetate

(2s,3s,5e)-1-[(2r,3r,5r)-3-(acetyloxy)-5-[(3-bromopropa-1,2-dien-1-yl)oxy]oxolan-2-yl]-3-bromooct-5-en-2-yl acetate

C19H26Br2O6 (508.0096)